Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
Ten dogs with transitional cell carcinoma (TCC) of the bladder were treated with a combination of once-weekly coarse fraction radiation therapy (six weekly fractions of 5.75 Gray [Gy]), mitoxantrone chemotherapy, and piroxicam. All dogs completed the radiation therapy protocol, and only minimal side effects were observed. Only two (22%) dogs achieved a measurable partial response; however, 90% of the dogs had amelioration of their urinary clinical signs. The median survival time for all dogs was 326 days. While this treatment protocol was well tolerated, the response rate and overall survival duration was not superior to reports using mitoxantrone and piroxicam without radiation therapy in dogs with TCC.
Poirier
Valerie J
VJ
School of Veterinary Medicine and the Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
Forrest
Lisa J
LJ
Adams
William M
WM
Vail
David M
DM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D003131:Combined Modality Therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000532:radiotherapy*; D004285:Dogs; D005260:Female; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use*; D010865:Pilot Projects; D010894:Piroxicam / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*
D000970:Antineoplastic Agents; D010894:Piroxicam; D008942:Mitoxantrone